onc Videos

Videos

Videos

Second-Line Cilta-cel Improves Outcomes for Patients With Functional High-Risk Multiple Myeloma vs Standard of Care Therapy

06/07/2024

Featuring Luciano Costa, MD

Cilta-cel improved outcomes for patients with lenalidomide-refractory functional high-risk multiple myeloma vs standard of care, according to data presented by Luciano Costa, MD, at the 2024 ASCO Annual Meeting.

Cilta-cel improved outcomes for...

06/07/2024

Oncology

Conference Coverage

Belantamab Mafodotin Plus Bortezomib and Dexamethasone Demonstrates Efficacy for Patients With R/R Multiple Myeloma

06/07/2024

Featuring Maria-Victoria Mateos, MD, PhD

Featuring Maria-Victoria Mateos, MD, ...

Maria-Victoria Mateos, MD, PhD, presents results from the phase 3 DREAMM-7 trial, which demonstrated the efficacy of belantamab mafodotin plus bortezomib and dexamethasone as a potential new standard of care for patients with R/R MM.

Maria-Victoria Mateos, MD, PhD,...

06/07/2024

Oncology

Rebecca Shatsky, MD, University of California, San Diego

Videos

Datopotamab Deruxtecan Plus Durvalumab for Certain Patients With Advanced Breast Cancer

06/07/2024

Rebecca Shatsky, MD

Rebecca Shatsky, MD, shares results on datopotamab deruxtecan plus durvalumab for certain patients with advanced breast cancer from the I-SPY2.2 trial.

Rebecca Shatsky, MD, shares...

06/07/2024

Oncology

Robert Rifkin, MD, Rocky Mountain Cancer Centers

Conference Coverage

Prophylactic Tocilizumab Prior to Outpatient Step-Up Administration of Teclistamab Lowers CRS Among Patients With R/R MM

06/04/2024

Featuring Robert Rifkin, MD

Robert Rifkin, MD, discusses results from a phase 2 study that evaluates outpatient step-up administration of teclistamab among patients with relapsed/refractory multiple myeloma.

Robert Rifkin, MD, discusses...

06/04/2024

Oncology

David Andorsky, MD, Rocky Mountain Cancer Centers

Videos

Significance of Patient Enrollment in Lymphoma Clinical Trials, Particularly Among Older Patients

06/04/2024

Featuring David Andorsky, MD

David Andorsky, MD, shares expert insight on the significance of clinical trials in lymphoma research, focusing on the inclusion of older patients in these studies.

David Andorsky, MD, shares...

06/04/2024

Oncology

Videos

Novel Updates in DLBCL and MCL Treatment Research From the 2024 ASCO Meeting

06/04/2024

Featuring John Burke, MD

John Burke, MD, discusses some of the most compelling topics in diffuse large B-cell lymphoma and mantle cell lymphoma research presented at the 2024 ASCO Annual Meeting.

John Burke, MD, discusses some...

06/04/2024

Oncology

Conference Coverage

Trastuzumab Deruxtecan for Patients With HER2-Low Metastatic Breast Cancer

06/03/2024

Xichun Hu, MD, PhD

Xichun Hu, MD, PhD, Fudan University Cancer Institute, Shangai, China, discussed results from the DESTINY-Breast06 trial which identified trastuzumab deruxtecan as a potential new standard of care for patients with HER2-Low metastatic breast...

Xichun Hu, MD, PhD, Fudan...

06/03/2024

Oncology

Conference Coverage

Immunotherapy Shows Activity Among Patients With Gynecologic Clear Cell Carcinoma

06/03/2024

Don Dizon, MD

Don Dizon, MD, discusses the results from the phase 2 BrUOG 354 trial evaluating nivolumab with/without ipilimumab among patients with ovarian and extra-renal clear cell carcinoma.

Don Dizon, MD, discusses the...

06/03/2024

Oncology

Conference Coverage

Datopotamab Deruxtecan for Patients With Previous Treated HR-Positive, HER2-Negative Breast Cancer

06/03/2024

Jane Meisel, MD

Jane Meisel, MD, discussed results from the I-SPY 2.2 trial which investigated the clinical activity of datopotamab deruxtecan among patients with HR-positive, HER2-negative breast cancer.

Jane Meisel, MD, discussed...

06/03/2024

Oncology

Conference Coverage

Subcutaneous Epcoritamab Demonstrated Efficacy Among Patients With R/R DLBCL and FL Treated in the Outpatient Setting

06/03/2024

Featuring David Andorsky, MD

David Andorsky, MD, discussed results from the phase 2 EPCORE NHL-6 trial, which showed that patients with R/R DLBCL and FL who were treated with subcutaneous epcoritamab demonstrated positive results in the outpatient setting.

David Andorsky, MD, discussed...

06/03/2024

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology